ReviewNeurological research and practice2026
Atrial fibrillation in stroke patients: facts, numbers and current challenges.
Review in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is a leading, modifiable risk factor for ischaemic stroke, with 20-30% of stroke patients harbouring underlying AF. Management of AF, however, differs substantially depending on clinical context. In ischaemic stroke patients with pre-known AF, direct oral anticoagulants (DOACs) are the cornerstone of secondary prevention, with initiation timing guided by infarct severity following a risk-adapted approach. In patients with no history of AF, prolonged cardiac rhythm monitoring after stroke or transient ischaemic attack improves AF detection rates. However, it remains uncertain whether this translates into a reduced risk of recurrent stroke, with randomised trials such as Find-AF 2 ongoing. Subclinical AF, detected via implantable devices, is associated with an increased stroke risk correlating with arrhythmia burden; recent trials (ARTESiA, NOAH-AFNET 6) suggest that anticoagulation may reduce ischaemic stroke risk in this population, but at the cost of increased bleeding, necessitating individualised decision-making. Particularly challenging are anticoagulation decisions with concomitant cerebral amyloid angiopathy or prior intracerebral haemorrhage (ICH) due to competing risks of thromboembolism and haemorrhage. Recent meta-analyses indicate that resuming DOACs after ICH reduces ischaemic events but significantly raises the risk of recurrent haemorrhage, without clear improvement in net clinical benefit. New treatment options, such as left atrial appendage closure, carotid artery filter systems, factor XIa inhibitors or rhythm control, must demonstrate in adequately powered randomised controlled trials that they can optimise treatment outcomes in this complex and growing patient group. This article summarises some common interdisciplinary neurological and cardiological questions and discusses the most recent evidence on AF-related stroke prevention across various patient groups, highlighting the importance of individualised, multidisciplinary, and imaging-informed decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.